|
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Eight patients (all females; age range 35-75 years) with biochemically proven insulinoma and with negative or inconclusive conventional imaging (consisting of somatostatin receptor scintigraphy, computed tomography, endoscopic ultrasound and magnetic resonance imaging) were enrolled.
|
31098984 |
2020 |
|
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These limitations prompted the development of innovations such as radiolabelled somatostatin receptor antagonists for imaging all types of NET and glucagon-like peptide-1 receptor agonists for the imaging of insulinomas.
|
30852831 |
2019 |
|
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Forty-three insulinomas stained negative for somatostatin receptor subtype 2a.
|
31369096 |
2019 |
|
insulinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Benign insulinomas express the glucagon-like peptide-1 receptor (GLP-1R, which recognizes exendin-4 and low levels of the somatostatin receptor (SSTR, which recognizes octreotide), whereas malignant insulinomas overexpress SSTR and low levels of GLP-1R.
|
28953210 |
2017 |
|
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interestingly, these three tracers appear to represent a spectrum of differentiation, which we conceptually describe as the 'triple-flop' phenomenon, with GLP-1R > SSTR > FDG in benign insulinoma and the opposite in higher-grade disease.
|
28400403 |
2017 |
|
insulinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mouse insulinoma cell line MIN6 cells were cultured with OCT to clarify its antiproliferative effects, the expression of somatostatin receptor subtypes, cell cycle, p27 expression, and cdc2 kinase activity.
|
24694834 |
2014 |
|
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, most of the somatostatin receptor-negative NET and GLP-1 receptor-negative malignant insulinomas are GIP receptor positive.
|
22112810 |
2012 |
|
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Many endocrine tumors express somatostatin receptors (sstrs), which can be visualized by octreotide scintigraphy; however, about half of all insulinomas are reported to be negative.
|
17916997 |
2007 |
|
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The observed positive correlation between SSTR5 expression and tumour size suggests that the use of SST analogues more specific to SSTR5 in the treatment of insulinomas deserves attention.
|
16601280 |
2006 |
|
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
(125)I-Tyr(0)DTrp(8)SRIF(14) binding was assessed by quantitative autoradiography in 18 insulinomas, and competition experiments were performed with SRIF(14) and L797-591, L779-976, L796-778, L803-087, L817-818, selective agonists of the five sst subtypes, and BIM23244, a selective agonist of sst2 and sst5.
|
14602773 |
2003 |